Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Ligand Pharmaceuticals (LGND) Preferred Stock Liabilities: 2011

Ligand Pharmaceuticals' Preferred Stock Liabilities was N/A to $8.3 million in Q4 2011 from the same period last year, while for Dec 2011 it was $8.3 million, marking a year-over-year change of. This contributed to the annual value of $8.3 million for FY2011, which is N/A change from last year.
According to the latest figures from Q4 2011, Ligand Pharmaceuticals' Preferred Stock Liabilities is $8.3 million.
Ligand Pharmaceuticals' 5-year Preferred Stock Liabilities high stood at $8.3 million for Q4 2011, and its period low was $8.3 million during Q4 2011.
Moreover, its 1-year median value for Preferred Stock Liabilities was $8.3 million (2011), whereas its average is $8.3 million.